Navigation Links
PharmaNet Development Group Announces Observational Research Survey

PRINCETON, N.J., Oct. 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries announced today the availability of a new survey on pharmaceutical Observational Research, the fourth in an on-going series. The survey is open to all in the industry with an interest in observational research and can be accessed here through October 31, 2010.  

Jeff Trotter,  Executive Vice President, Phase IV Development, and creator of the survey, remarked, "Pharmaceutical companies are increasingly looking to prospective Observational Research for compiling real world data on post-approval clinical performance, economic value, patient quality-of-life, and product safety. While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately-designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians and patients."

Previous surveys have revealed that drug development organizations can benefit from broader cross-functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.

The results of this survey, plus the findings identified in previous surveys, are expected to be released in November.  If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, please contact  

About PharmaNet Development Group, Inc.PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at  Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
4. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Promising Cystic Fibrosis Compound on Track for Development
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... and athletic programs, launches new Wimbledon Athletics Facebook page to educate ... athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 ...
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... for people struggling with eating disorders as a result of the $20,000 raised ... event, held at Fox Run Golf Club in Eureka, will help individuals who ...
Breaking Medicine News(10 mins):